IBJNews

Lilly partner moves up timetable for diabetes drug

Back to TopCommentsE-mailPrintBookmark and Share

Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.

The San Diego-based company may finish the study early if the Food and Drug Administration allows a less complex design, CEO Daniel Bradbury said in an interview Monday at the J.P. Morgan Healthcare Conference in San Francisco.

Amylin lost about half its market value Oct. 20 after saying the FDA wanted a study assessing the drug’s heart risks, though the shares have since gained almost half of the lost value. Bydureon is a longer-acting version of the twice-daily diabetes injection Byetta sold by Amylin and Indianapolis-based Eli Lilly and Co.

A weekly drug would be more convenient for patients and help the company compete with Novo Nordisk A/S of Bagsvaerd, Denmark, the world’s biggest maker of insulin.

“We will initiate the study in the first quarter and we remain very confident that we will be able to complete the required work by the end of 2011,” Bradbury said.

Byetta, a synthetic version of a substance found in the saliva of the Gila monster, stimulates pancreas cells to produce the hormone insulin when blood sugar is high. It had worldwide sales of $796.5 million in 2009. Sales fell 18 percent in the third quarter of 2010, to $168.8 million, Lilly said on Oct. 21.

Lilly attributed the drop to competition in the U.S. and German markets. A new Novo drug, Victoza, entered the market last year. While similar to Byetta, it can be taken once a day instead of twice.

Joshua Schimmer, an analyst for Leerink Swann, said Amylin may complete and submit the heart-safety studies by the middle of this year and win approval for Bydureon by the end of the year. Bydureon revenue may reach $600 million in 2014, pushing combined revenue for Bydureon and Byetta to $965 million, Schimmer said in a Jan. 4 note to investors.

Amylin said in October it would submit the heart-safety study by the end of 2011.

Lilly markets Byetta outside the U.S. and co-markets it with Amylin in the U.S. The drug was developed by Amylin, and the technology enabling it to be used in a longer-acting form was developed by Waltham, Mass.-based Alkermes Inc. Alkermes will receive royalties of about 8 percent on Bydureon sales.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT